{"classes":[{"categories":[{"measurements":[{"comment":"Median could not be calculated due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"3.3","upperLimit":"19.6","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"OS was defined as the time from the start of any study treatment to the date of death due to any cause. OS was calculated as date of death minus date of first dose of any study treatment plus 1. OS for participants who were alive at their date of last contact, including those lost to follow-up, were censored at the date of last contact. If the last recorded date where a participant was known to be alive is the date of first dose of any study treatment, survival time was censored on the date of first dose of any study treatment (i.e., OS duration of 1 day).","dispersionType":"Full Range","groups":[{"description":"Participants received SEA-BCMA 1600 mg IV q2wk on Day 1 and 15 of each 28-day cycle, dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 and pomalidomide 4 mg orally, daily from Day 1 to 21 of each of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part D: SEA-BCMA 1600 mg, Pomalidomide and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From date of start of study treatment until date of death or censoring date (maximum up to 20 months)","title":"OS: Part D","type":"SECONDARY","unitOfMeasure":"Months"}